Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GUCY1A1 | Q02108 | 2/20 | 0.38 |
| ▸ | GUCY1B1 | Q02153 | 2/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20140434 | 0.91 | L3MBTL1 (0.46) | MAPTL3MBTL1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL20140374 | 0.86 | L3MBTL1 (0.49) | MAPTL3MBTL1KDM4ECYP1A2CYP2C19 | |
| SCHEMBL20140776 | 0.86 | ELANE (0.42) | MAPTL3MBTL1ELANE | |
| SCHEMBL20140783 | 0.84 | L3MBTL1 (0.63) | L3MBTL1KDM4EELANEALDH1A1PKM | |
| SCHEMBL2881342 | 0.82 | ELANE (0.41) | MAPTL3MBTL1ELANE | |
| SCHEMBL2877930 | 0.82 | ELANE (0.41) | MAPTL3MBTL1KDM4EELANEENPP2 | |
| SCHEMBL2882941 | 0.81 | ELANE (0.44) | MAPTL3MBTL1KDM4EELANEKMT2A | |
| SCHEMBL20140277 | 0.79 | ELANE (0.46) | L3MBTL1KDM4EELANEALDH1A1CYP11B1 | |
| SCHEMBL20140381 | 0.79 | ELANE (0.56) | L3MBTL1ELANEKMT2AMEN1 | |
| SCHEMBL20140295 | 0.79 | ELANE (0.44) | MAPTL3MBTL1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435080-B2 | sGC stimulators | TISENTO THERAPEUTICS INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
| EP-3538520-A2 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018089330-A2 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20100004235-A1 | Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses | BAYER HEALTHCARE AG (DE) | 2010-01-07 | — | — | US | disclosed |
| US-20100004235-A1 | Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses | BAYER HEALTHCARE AG (DE) | 2010-01-07 | — | — | US | disclosed |
| US-20100004235-A1 | Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses | BAYER HEALTHCARE AG (DE) | 2010-01-07 | — | — | US | disclosed |
| EP-2013205-A1 | HETEROCYCLIC SUBSTITUTED, ANELLATED PYRAZOLE DERIVATIVE AND ITS USES | Bayer HealthCare AG (DE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007124854-A1 | HETEROCYCLIC SUBSTITUTED, ANELLATED PYRAZOLE DERIVATIVE AND ITS USES | BAYER HEALTHCARE AG (DE) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007124854-A1 | HETEROCYCLIC SUBSTITUTED, ANELLATED PYRAZOLE DERIVATIVE AND ITS USES | BAYER HEALTHCARE AG (DE) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071318-A1 | SGC STIMULATORS | GUCY1A2, GMPS, PDE2A | MAPT 4780/4885L3MBTL1 4698/4885KDM4E 3627/4885 |
| US-20220017515-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, PDE2A | MAPT 4786/4885L3MBTL1 4695/4885KDM4E 3552/4885 |
| US-12435080-B2 | sGC stimulators | GUCY1A2, PRKG1, PDE2A | MAPT 4786/4885L3MBTL1 4695/4885KDM4E 3552/4885 |
| US-20100004235-A1 | Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses | AADAC, CYP11B2, PC | MAPT 4591/4885L3MBTL1 3320/4885KDM4E 4565/4885 |
| US-11180493-B2 | SGC stimulators | GUCY1A2, GMPS, PDE2A | MAPT 4780/4885L3MBTL1 4698/4885KDM4E 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.